全文获取类型
收费全文 | 709篇 |
免费 | 23篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 30篇 |
妇产科学 | 5篇 |
基础医学 | 65篇 |
口腔科学 | 3篇 |
临床医学 | 15篇 |
内科学 | 61篇 |
皮肤病学 | 1篇 |
神经病学 | 342篇 |
外科学 | 15篇 |
综合类 | 1篇 |
预防医学 | 22篇 |
眼科学 | 1篇 |
药学 | 160篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 7篇 |
2018年 | 7篇 |
2017年 | 5篇 |
2016年 | 11篇 |
2015年 | 15篇 |
2014年 | 11篇 |
2013年 | 26篇 |
2012年 | 38篇 |
2011年 | 37篇 |
2010年 | 8篇 |
2009年 | 16篇 |
2008年 | 32篇 |
2007年 | 37篇 |
2006年 | 42篇 |
2005年 | 47篇 |
2004年 | 51篇 |
2003年 | 46篇 |
2002年 | 35篇 |
2001年 | 40篇 |
2000年 | 38篇 |
1999年 | 44篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 2篇 |
1992年 | 13篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 8篇 |
1988年 | 14篇 |
1987年 | 12篇 |
1986年 | 8篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有736条查询结果,搜索用时 0 毫秒
61.
Stryjer R Strous RD Bar F Werber E Shaked G Buhiri Y Kotler M Weizman A Rabey JM 《Clinical neuropharmacology》2003,26(1):12-17
Comorbid schizophrenia and dementia is a common clinical phenomenon; however, management of the coexisting illnesses remains incomplete. Donepezil, a cholinesterase inhibitor, may be beneficial for the management of symptoms of Alzheimer's disease, a disease in which cholinergic pathways in the cerebral cortex and basal forebrain are well known to be compromised. Furthermore, impaired cognition in elderly schizophrenic patients has been observed to be more than two thirds; however, there are no published controlled studies reporting the use of cholinesterase inhibitors in the management of schizophrenia in patients with associated dementia. In this study, six patients with chronic schizophrenia and comorbid dementia were administered donepezil, 5 mg, in single-blind fashion as augmentation to their standard antipsychotic medication for a 4-week period. Patients were evaluated with the Mini Mental State Examination (MMSE); Alzheimer's Disease Assessment Scale, Cognitive subscale; Positive and Negative Symptom Scale (PANSS); and the Clinical Global Impression (CGI) scales. A significant improvement was noted in MMSE scores (P < 0.01) and for CGI scores (P < 0.01). In addition, three patients demonstrated improvement on the PANSS. Donepezil appears to be an effective treatment for the management of symptoms of dementia accompanying patients with comorbid schizophrenia and dementia. Since cholinergic dysfunction may be present in some patients with schizophrenia, the authors' findings further demonstrate the possibility that this disorder may be managed with cholinergic medications as augmenting agents, at least in this specific subpopulation of patients with comorbid dementia. To confirm the findings of this preliminary trial, further investigation is mandated with a larger sample of subjects in the context of a double-blind medication trial. 相似文献
62.
The present study describes two patients, both of Yemenite origin, with catatonic schizophrenia who responded to treatment with risperidone. One had a long history of psychiatric disorder, whereas the other was a first-episode, drug-naive patient. Our observation agrees with previous reports on the use of risperidone and other novel neuroleptic agents in the treatment of catatonia of different etiologies. 相似文献
63.
Spivak B Mozes T Mester R Kodelik M Weizman A 《Journal of child and adolescent psychopharmacology》2001,11(3):279-284
The present open-label study assessed the efficacy of zuclopenthixol, an thioxanthene neuroleptic with combined dopamine receptors (D1/D2) antagonist activity, in the treatment of severe behavioral disturbances in mentally retarded children and adolescents. A sample of 15 (11 males, 4 females) mentally retarded children and adolescents, ages 5-18 years (12.2 +/- 2.3 [mean +/- SD] years), all exhibiting severe behavioral disturbances, was evaluated. The 12-week zuclopenthixol treatment (up to 26 mg/day) was initiated after a week's washout from previous antipsychotic agents. An assessment of the behavioral disturbances was performed using the 14-item Checklist for Behavior Problems Involving Limited or No Social Awareness (CBP-NSA). The Udvalg for kliniske unders?gelser (UKU) Side Effect Rating Scale was used to assess the pharmacologic side effects. Results show a significant reduction in total CBP-NSA scores and in individual items such as hyperactivity, aggressive behavior, and temper tantrums (p < 0.001 for each). It seems that zuclopenthixol monotherapy is effective and well tolerated in the treatment of severe behavioral disturbances in mentally retarded children and adolescents. Double-blind, placebo-controlled studies are needed before definitive conclusions can be drawn regarding the efficacy and safety of zuclopenthixol for this population. 相似文献
64.
The brain is a highly sophisticated assembly of neuronal networks for interaction with the internal and external environment. Fundamentally, the neuronal communication process is analogous structurally and functionally to the electrical (wire-mediated) network. In particular, both have coupled information-processing and conduction properties. We suggest that the electrical system can be used as a learning paradigm in brain research and clinical practice. Our model shows how the study of wire-mediated networks may be of benefit in tracing overt psychiatric manifestations to intrinsic biological faults in brain circuitry. 相似文献
65.
Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? 总被引:4,自引:0,他引:4
To determine whether selectivity for serotonin reuptake plays a role in antidepressant-associated mania (AAM), we evaluated the frequency of treatment-emergent mania in patients with unipolar depression who received either citalopram, a highly selective serotonin uptake inhibitor, or the adrenergic tetracyclic antidepressants (TTCAs) maproriline and mianserin, or placebo. Data were collected from post-marketing reports of adverse events, three placebo-controlled trials and four double-blind comparative trials. Of the total 4,004 depressed patients treated with citalopram (2482 from postmarketing data, 840 from placebo-controlled studies and 682 from TTCAs comparative studies), 25 (0.62%) had manic episodes. The rate of AAM in the comparative trials was significantly lower in the citalopram-treated patients (1/682, 0.15%) than in the TTCA-treated patients (5/389, 1.29%) (P = 0.03). In the placebo-controlled studies, no manic episodes were reported in the patients given placebo, but one manic episode occurred in a citalopram-treated patient (1/840, 0.12%). The citalopram-treated patients in whom AAM developed were significantly older than those in whom it did not (about 10 years, P < 0.001); gender distribution was similar. In conclusion, despite its limitations, our study apparently indicates that citalopram, a highly selective serotonin reuptake inhibitor, is associated with a significantly lower rate of treatment-emergent manic episodes than TTCAs, which have noradrenergic activity, but a similar rate to that reported for less selective SSRIs. 相似文献
66.
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms 总被引:3,自引:0,他引:3
Poyurovsky M Dorfman-Etrog P Hermesh H Munitz H Tollefson GD Weizman A 《International clinical psychopharmacology》2000,15(3):169-173
Some studies suggest that obsessive-compulsive symptoms may be common (7.8-46%) in schizophrenic patients and seem to be poorly responsive to drug therapy. Conventional neuroleptics are of limited value, but adjunctive anti-obsessive agents (clomipramine, fluvoxamine) may be an option. Although novel atypical antipsychotics (clozapine, risperidone) reportedly aggravate the obsessive-compulsive symptoms, a recent trial has shown that olanzapine did not induce new-onset obsessive-compulsive symptoms in schizophrenic patients. We report our experience with three schizophrenic patients with obsessive-compulsive symptoms who were unsuccessfully treated with various conventional neuroleptics in combination with anti-obsessive agents and subsequently showed resistance or intolerance to clozapine. All of them were switched to olanzapine (10-20 mg/ day). All patients demonstrated a significant improvement in both schizophrenic and obsessive-compulsive symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Within 5-8 weeks of initiation of olanzapine, the BPRS scores of the three patient decreased by 53%, 51% and 48%, and the Y-BOCS scores by 68%, 73% and 85%. Olanzapine was well tolerated. These preliminary results suggest that olanzapine may be a therapeutic option in schizophrenic patients with obsessive-compulsive symptoms. 相似文献
67.
Amir Krivoy Abraham Weizman Lucian Laor Nurit Hellinger Zvi Zemishlany Tsvi Fischel 《European neuropsychopharmacology》2008,18(2):117-121
BACKGROUND: Schizophrenia is comprised of several debilitating symptoms. Antipsychotics offer an effective treatment for positive symptoms, while the negative signs and cognitive deficits are usually treatment-resistant. It was suggested that glutamate dysregulation may be involved in the neuropathology of schizophrenia, mainly through NMDA dysfunction. We hypothesized that addition of memantine, a weak non-selective NMDA receptor antagonist approved for dementia, to antipsychotics would improve the clinical status of un-remitted schizophrenia patients, notably the negative signs and cognitive deficits. METHODS: Seven schizophrenia patients, were included in a six-week open-label study, with weekly increasing dosage (5, 10, 15, 20 mg) of memantine added to their on-going antipsychotic treatment. RESULTS: We found a significant improvement of the PANSS score (baseline 116.28+/-21.9 vs. 97.86+/-24.48 after six weeks, t=5.98, p<0.001) with the most prominent improvement (21%) in negative signs sub-scale (baseline 40+/-6.38 vs. 31.71+/-7.76 after six weeks, t=5.87, p<0.001). Cognitive status, measured with the Neurobehavioral Cognitive Examination (NCSE) and Clock Drawing Test (CDT) showed no improvement. CONCLUSION: Memantine addition to antipsychotic treatment, in schizophrenia patients might improve their clinical status, primarily the negative signs, but not their cognitive deficits. Further research is needed to replicate these observations. 相似文献
68.
Lack of effect of 28 days of neuroleptic treatment on platelet benzodiazepine binding sites in schizophrenics 总被引:2,自引:0,他引:2
Twenty-eight days of neuroleptic treatment of 11 schizophrenics aged 16-23 years did not affect the binding values of 3H-PK 11195 to platelets. This lack of effect was in contrast to reduced peripheral benzodiazepine binding sites (PBS) observed in platelets of schizophrenics medicated over 2 years. These results may indicate that neuroleptic-induced down-regulation of PBS is a time-dependent phenomenon. 相似文献
69.
B Spivak A Weizman L Wolovick H Hermesh S Tyano H Munitz 《Acta psychiatrica Scandinavica》1990,81(2):168-169
Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described. This case, although rare and atypical, should alert clinicians to consider the possibility of NMS as a complication of abrupt neuroleptic drug withdrawal. It is suggested that dopaminergic imbalance, as opposed to excessive dopaminergic blockade, may also play a role in the precipitation of NMS. 相似文献
70.